{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T09:20:08Z","timestamp":1720776008057},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jdcr.2023.09.037","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:05:41Z","timestamp":1697378741000},"page":"68-70","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Resolution of long standing hypergammaglobulinemic purpura of Waldenstr\u00f6m after initiating treatment for cystic fibrosis with Elexacaftor\u2013Tezacaftor\u2013Ivacaftor"],"prefix":"10.1016","volume":"44","author":[{"given":"Kimberly","family":"Tantuco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2023.09.037_bib1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2013.02.020","article-title":"JAAD grand rounds. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenstr\u00f6m)","volume":"72","author":"Mathis","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.09.037_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/096120339500400105","article-title":"Hypergammaglobulinemic purpura of Waldenstr\u00f6m associated with systemic lupus erythematosus: report of a case and review of the literature","volume":"4","author":"Habib","year":"1995","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.jdcr.2023.09.037_bib3","first-page":"1030","article-title":"Purpuric rashes in cystic fibrosis","volume":"143","author":"Schidlow","year":"1989","journal-title":"Am J Dis Child"},{"issue":"4","key":"10.1016\/j.jdcr.2023.09.037_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0190-9622(90)70271-I","article-title":"Hypergammaglobulinemic purpura of Waldenstr\u00f6m","volume":"23","author":"Finder","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.09.037_bib5","first-page":"518","article-title":"Hypergammaglobulinemic purpura of Waldenstr\u00f6m: report of 3 cases with a short review","volume":"18","author":"Malaviya","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"9358","key":"10.1016\/j.jdcr.2023.09.037_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jdcr.2023.09.037_bib7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1513\/AnnalsATS.201802-075FR","article-title":"Cystic fibrosis: translating molecular mechanisms into effective therapies","volume":"15","author":"Jennings","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jdcr.2023.09.037_bib8","article-title":"A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jdcr.2023.09.037_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/pde.14120","article-title":"Hypergammaglobulinemic purpura of Waldenstr\u00f6m in children","volume":"37","author":"Theisen","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jdcr.2023.09.037_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.1989.tb08199.x","article-title":"Cutaneous manifestations of cystic fibrosis: possible role of cryoglobulins","volume":"121","author":"Garty","year":"1989","journal-title":"Br J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623003831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623003831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:58:27Z","timestamp":1718895507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":10,"alternative-id":["S2352512623003831"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.09.037","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of long standing hypergammaglobulinemic purpura of Waldenstr\u00f6m after initiating treatment for cystic fibrosis with Elexacaftor\u2013Tezacaftor\u2013Ivacaftor","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}